Compare Charles River Laboratories Intl. Inc (CRL) vs Fabrinet (FN) Price & Performance

Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.

The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.

Fabrinet (FN) trades at $486.28, down 2.35% today but maintains strong analyst support with 75% buy ratings and a $769.50 consensus price target. The stock shows bullish technical signals with support at $477 and resistance at $498, while recent earnings beats highlight robust AI data-center demand driving 45% revenue growth in Q4 2026. Valuation metrics include a P/E of 37.34 and ROE of 21.33%, reflecting premium pricing for high growth.

Outlook remains positive with multi-year AI infrastructure expansion, though risks include customer concentration and margin pressure from capital expenditures. The stock offers significant upside to analyst targets if execution continues, but volatility may persist near current levels.